SEC Filing Summary: Cortxyme, Inc. (CRTX)
Business Context and Reporting Period
This Form 8-K was filed by Cortxyme, Inc. (not Quince Therapeutics, Inc.) on May 18, 2020. The registrant is a Delaware corporation with principal executive offices in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market under the symbol CRTX. The company is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements.
Material Changes
Between May 18, 2020, and May 21, 2020, the Company entered into Executive Change in Control and Severance Agreements ("CiC Agreements") with six Executive Officers: Casey C. Lynch, Michael Detke, M.D., Stephen S. Dominy, M.D., Leslie Holsinger, Ph.D., Christopher Lowe, and Caryn McDowell. These agreements establish specific severance benefits triggered by terminations without "cause" or resignations for "good reason."
Guidance, Outlook, and Management Commentary
The filing details the terms of the CiC Agreements:
- Change in Control Period (CiC Period): Defined as the period beginning 3 months prior to and ending 18 months following a change in control.
- Termination within CiC Period:
- Casey C. Lynch: 18 months base salary, 150% target annual bonus, 18 months COBRA premiums, and full vesting acceleration of time-based and performance-based equity awards.
- Other Executives: 12 months base salary, 100% target annual bonus, 12 months COBRA premiums, and full vesting acceleration of time-based and performance-based equity awards.
- Termination Outside CiC Period:
- Casey C. Lynch: 12 months base salary and applicable COBRA premiums.
- Other Executives: Base salary for a period based on tenure (3 months for <12 months tenure, 6 months for 12-24 months tenure, 9 months for >24 months tenure) and applicable COBRA premiums.
- Excise Tax Reduction: Payments may be reduced if they constitute "parachute payments" under Section 280G of the Internal Revenue Code to avoid excise tax under Section 4999.
Investor Verification Checklist
- Verify the full text of the Executive Change in Control and Severance Agreement filed as Exhibit 10.1.
- Confirm the specific definitions of "cause" and "good reason" within the agreements to understand termination triggers.
- Assess the potential financial impact of equity vesting acceleration on the company's capital structure.
- Review the company's current cash position to evaluate its ability to fund these potential severance obligations.